Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure

2014 ◽  
Vol 171 (3) ◽  
pp. 398-403 ◽  
Author(s):  
Kazuhide Ogino ◽  
Yoshiharu Kinugasa ◽  
Masahiko Kato ◽  
Kazuhiro Yamamoto ◽  
Ichiro Hisatome ◽  
...  
2007 ◽  
Vol 13 (6) ◽  
pp. S142-S143
Author(s):  
Kazuhide Ogino ◽  
Masahiko Kato ◽  
Yoshiyuki Furuse ◽  
Yoshiharu Kinugasa ◽  
Katsunori Ishida ◽  
...  

2008 ◽  
Vol 52 (3) ◽  
pp. 239 ◽  
Author(s):  
Wolfram Doehner ◽  
Stephan von Haehling ◽  
Stefan D. Anker

2014 ◽  
Vol 5 (1) ◽  
pp. 33-40
Author(s):  
S. V Kakorin ◽  
I. A Averkova ◽  
A. M Mkrtumyan

The article presents a literature review of prevalence, prognosis and treatment of overt tactics of chronic heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM). Application of modern pharmacological preparations and instrumental treatment of cardiovascular disease (CVD) increases life expectancy and improves the quality of life of patients with CHF as with normal carbohydrate metabolism (UO), and with type 2 diabetes. However, the risk of cardiovascular mortality (CAS) in patients with type 2 diabetes, compared to having a normal carbohydrate metabolism remains unchanged.Insulin resistance (IR) and compensatory hyperinsulinemia (GI) play a key role in the pathogenesis of type 2 diabetes. Ongoing research in the twentieth century of coronary heart disease (CHD) and heart failure in patients with type 2 diabetes revealed adverse effects of sulfonylurea medications on the metabolic processes in the myocardium and increased risk of death in patients with severe coronary artery disease. In comparison with sulfonylurea drugs, metformin and insulin not only reduces the risk of cardiovascular disease, but also can prevent or delay the development of type 2 diabetes in individuals with impaired glucose tolerance (IGT) and impaired fasting glucose. Metformin acts on the key link of pathogenesis - insulin resistance, affecting the lower incidence of cardiovascular diseases, the development of chronic disease and mortality compared with insulin and sulfonylurea drugs. However, in patients with chronic heart failure is contraindicated the use of thiazolidinediones and metformin is limited tothe severity of CHF I-II FC NYNA. With effective treatment of chronic heart failure by cardiologists in patients with type 2 diabetes, affecting therapy with insulin resistance should be mandatory.


2008 ◽  
Vol 7 ◽  
pp. 106-107
Author(s):  
G MARAZZI ◽  
M VOLTERRANI ◽  
G CAMINITI ◽  
R MASSARO ◽  
C MAMMI ◽  
...  

2020 ◽  
Vol 24 (5) ◽  
pp. 29-36
Author(s):  
M. E. Statsenko ◽  
S. V. Fabritskaya ◽  
Y. A. Ryndina

THE AIM: to study the functional state ofthe kidneys in patientswith chronic heart failure (CHF)and obesity. PATIENTS AND METH­ODS. 116 patients with CHF l-lll functional class (FC) 45-65 years old are divided into three comparable groups depending on body mass index (BMI). A physical examination was performed, evaluated the renal function, the level of leptin and adiponectin, assessed the insulin resistance index, the combined risk of progression of chronic kidney disease (CKD), and the development of cardiovascular complications was analyzed. RESULTS. Among patients with CHF and obesity, a statistically significant decrease in glomerular filtration rate (GFR) was observed compared with patients of the 1st group (61.3 [46.2; 67.1] vs 73.2 [62.1; 86.3] ml/min / 1.73 m2), a clinically significant decrease in GFR <60 ml/min /1.73 m2 (CKD C3a-3b), high (A2) and very high (A3) albu­minuria (AU) compared in patientswith normal and overweight. The leptin concentration significantly increased from the 1st to the 3rd group, while the adiponectin concentration decreased from the 1st to the 3rd group. Statistically significant correlations were established between the concentration of leptin and GFR (r = -0.52), AC (r = 0.36), between the concentration of adiponectin and GFR (r = 0.38), AC (r = -0.32). Significant associations were found among patientswith overweight and obesity between the severity of AU, GFR, and HOMA-IR, metabolic index. CONCLUSION. A significant deterioration in the functional parameters ofthe kidneys in patientswith CHF with increasing body weight, as well as an increase in the combined risk of CKD progression and the development of cardiovascular complications with comparable FC, was established. The revealed reliable relationships reflect the significant pathogenetic contribution of the hormonal activity of visceral adipose tissue and insulin resistance to the development and progression of renal dysfunction in patients with heart failure and obesity.


2016 ◽  
Vol 94 (6) ◽  
pp. 439-444
Author(s):  
Mihail E. Statsenko ◽  
S. V. Turkina ◽  
N. N. Shilina ◽  
M. A. Kosivtsova

Patients with chronic heart failure and diabetes mellitus type 2 experience continuous progression of organ damage as a result of hemodynamic and metabolic disorders. An important role in pathogenesis of organ damage belongs to pathological types of microcirculation, endothelial dysfunction and insulin resistance. But the role of insulin resistance and its contribution to the formation of endothelial dysfunction and peculiarities of microcirculation in patients with chronic heart failure and type 2 diabetes mellitus is unknown. This study shows significant association between insulin resistance, disorders of carbohydrate and lipid metabolism, development of microcirculatory disturbances and endothelial dysfunction.


2002 ◽  
Vol 83 (1) ◽  
pp. 73-81 ◽  
Author(s):  
Wolfram Doehner ◽  
Mathias Rauchhaus ◽  
Ian F. Godsland ◽  
Karl Egerer ◽  
Josef Niebauer ◽  
...  

2003 ◽  
Vol 41 (6) ◽  
pp. 158
Author(s):  
Wolfram Doehner ◽  
Ian F. Godsland ◽  
Mathias Rauchhaus ◽  
Piotr P. Ponikowski ◽  
Andrew J. Coats ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document